InvestorsHub Logo
Followers 58
Posts 3913
Boards Moderated 0
Alias Born 04/23/2013

Re: ziploc_1 post# 421100

Saturday, 02/03/2024 11:54:07 AM

Saturday, February 03, 2024 11:54:07 AM

Post# of 425638
This new EPA delivery system (lymph-releasing composition of eicosapentaenoic acid ethyl ester (LR-EtEPA), reminds me of Matinas Biopharma (MTNB). Anyone remember these guys? Their product LYPDISCO was based on a novel drug delivery system called LNC (Lypid Nano-Crystal) which encapsulates the drug or agent in a hydrophobic bubble which protects it from oxidative stress until it is released into the target tissue. According to the Matinas website oral administration also works through the lymphatic system. LNC Platform :: Matinas BioPharma Holdings, Inc. (MTNB)

You may also recall that they conducted a head-to-head (ENHANCE-IT) against VASCEPA® which apparently showed greater bioavailability and TG reduction than VASCEPA®. The company subsequently received FDA approval for it’s LYPDISCO brand name. I recall hearing that they have since discontinued R&D on this product. Could MTNB be an M&A target for AMRN or does this new technology make LYPDISCO redundant?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News